Worth reading
34Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Partially revisedInvestment amount by sectorField Investment in H-1337 Phase 3 / Amount Not disclosed, Field Research and development to expand and advance the pipeline / Amount Not disclosed
Key initiatives
01Prioritize launching products in the Japanese market
02Create value through efficient development
03Expand U.S. development and licensing opportunities
04Pursue improved patient quality of life
05Develop once-daily eye drops
06Prioritize medication adherence
07Develop blockbuster products
08Begin work on combination products at an early stage
09Expand operations in Asia, Europe and the United States
10Explore other diseases
Plan assumptionsSteady royalty income from marketed products DW-1002, グラアルファ and DW-5LBT, including products covered by sales alliances, and progress in pipeline development, including the receipt of milestones for DW-1002, Steady progress in H-1337, DWR-2206 and H-1129
Size of the Target MarketMarket Japan / Scale Approximately ¥88.5 billion / Estimated patient population 4 million / Source Calculated by the Company based on the Ministry of Health, Labour and Welfare's 10th NDB Open Data and by applying a 5% prevalence rate to the 2024 population estimates from the Government Statistics Portal (e-Stat), Market United States / Scale Approximately $3 billion / Estimated patient population 4.2 million people / Source Calculated by the Company based on IQVIA MIDAS Dec 2020 MAT (Copyright © 2023 IQVIA) and information published on PubMed
Risks identified by the company
The above plan is based on the development plan assumed by the licensing partner or the Company's projections and may differ from actual development progress.
The development plan for H-1337 in Japan will be disclosed once finalized.
For DW-1001, the future development plan is under consideration based on the policy of the licensing partner, Rohto Pharmaceutical Co., Ltd.
Reason for revision or withdrawal
As stated in the Notice Regarding the Capital and Business Alliance and the Issuance of New Shares through a Third-Party Allotment disclosed today, the Company adopted a policy of prioritizing development in Japan for the glaucoma treatment H-1337. Accordingly, the development plan for H-1337 has been revised.
| Item | Details |
|---|---|
| Plan name | Business Plan and Growth Potential |
| Plan period | 2025–2028 |
| Progress against the plan | Partially revised |
| Investment amount by sector | Field Investment in H-1337 Phase 3 / Amount Not disclosed, Field Research and development to expand and advance the pipeline / Amount Not disclosed |
| Plan assumptions | Steady royalty income from marketed products DW-1002, グラアルファ and DW-5LBT, including products covered by sales alliances, and progress in pipeline development, including the receipt of milestones for DW-1002, Steady progress in H-1337, DWR-2206 and H-1129 |
| Key initiatives | Prioritize launching products in the Japanese market, Create value through efficient development, Expand U.S. development and licensing opportunities, Pursue improved patient quality of life, Develop once-daily eye drops, Prioritize medication adherence, Develop blockbuster products, Begin work on combination products at an early stage, Expand operations in Asia, Europe and the United States, Explore other diseases |
| Reason for revision or withdrawal | As stated in the Notice Regarding the Capital and Business Alliance and the Issuance of New Shares through a Third-Party Allotment disclosed today, the Company adopted a policy of prioritizing development in Japan for the glaucoma treatment H-1337. Accordingly, the development plan for H-1337 has been revised. |
| Size of the Target Market | Market Japan / Scale Approximately ¥88.5 billion / Estimated patient population 4 million / Source Calculated by the Company based on the Ministry of Health, Labour and Welfare's 10th NDB Open Data and by applying a 5% prevalence rate to the 2024 population estimates from the Government Statistics Portal (e-Stat), Market United States / Scale Approximately $3 billion / Estimated patient population 4.2 million people / Source Calculated by the Company based on IQVIA MIDAS Dec 2020 MAT (Copyright © 2023 IQVIA) and information published on PubMed |
| Risks identified | The above plan is based on the development plan assumed by the licensing partner or the Company's projections and may differ from actual development progress., The development plan for H-1337 in Japan will be disclosed once finalized., For DW-1001, the future development plan is under consideration based on the policy of the licensing partner, Rohto Pharmaceutical Co., Ltd. |
| Publication date | 25 March 2026 |
Items this document does not state (15)
Sales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planSegment targetNon-financial targetsResults under the previous planDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In light of the capital and business alliance and the issuance of new shares through a third-party allotment, the Company adopted a policy of prioritizing development in Japan for the glaucoma treatment H-1337.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.